MedPath

Oxybutynin

Generic Name
Oxybutynin
Brand Names
Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)
Drug Type
Small Molecule
Chemical Formula
C22H31NO3
CAS Number
5633-20-5
Unique Ingredient Identifier
K9P6MC7092

Overview

Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life. Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975. This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.

Indication

Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a neurological condition in which oxybutynin may be used to control urinary symptoms. On occasion, oxybutynin may be used off-label to relieve bladder spasms associated with ureteral stents or urinary catheters.

Associated Conditions

  • Bladder Spasms
  • Detrusor Hyperreflexia
  • Overactive Bladder Syndrome (OABS)

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2014/09/15
Phase 2
Completed
2014/06/27
Phase 4
Terminated
2014/03/31
Phase 3
Withdrawn
2013/10/08
N/A
Completed
2013/07/15
Phase 4
Completed
2013/05/16
Phase 3
Completed
2012/10/30
Phase 3
Completed
2012/03/19
Phase 3
Completed
2011/11/22
Not Applicable
Completed
Centro de Reabilitação e Readaptação Dr. Henrique Santillo
2011/08/26
Phase 4
UNKNOWN
Adana Numune Training and Research Hospital

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Rising Pharma Holdings, Inc.
64980-209
ORAL
5 mg in 1 1
3/29/2022
Chartwell RX, LLC
62135-508
ORAL
10 mg in 1 1
3/6/2023
Aphena Pharma Solutions - Tennessee, Inc.
43353-769
ORAL
10 mg in 1 1
3/26/2012
Physicians Total Care, Inc.
54868-4502
ORAL
10 mg in 1 1
2/16/2012
Physicians Total Care, Inc.
54868-5742
ORAL
5 mg in 1 1
1/21/2010
Ajanta Pharma USA Inc.
27241-156
ORAL
10 mg in 1 1
5/25/2023
Novitium Pharma LLC
70954-005
ORAL
5 mg in 1 1
8/24/2021
Ajanta Pharma USA Inc.
27241-157
ORAL
15 mg in 1 1
5/25/2023
Physicians Total Care, Inc.
54868-4835
ORAL
15 mg in 1 1
2/16/2012
Bryant Ranch Prepack
71335-1494
ORAL
5 mg in 1 1
5/23/2023

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

View More TGA Approvals

Sign in to access additional TGA-approved drug information with detailed regulatory data.

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
RIVA-OXYBUTYNIN
laboratoire riva inc.
02242109
Tablet - Oral
5 MG
5/5/2000
PAT-OXYBUTYNIN CHLORIDE ER
02420015
Tablet (Extended-Release) - Oral
15 MG
N/A
OXYBUTYNIN SYRUP
02230943
Syrup - Oral
1 MG / ML
N/A
DOM-OXYBUTYNIN 5 MG TABLETS
dominion pharmacal
02241285
Tablet - Oral
5 MG
12/16/1999
MYLAN-OXYBUTYNIN
Mylan Pharmaceuticals ULC
02230800
Tablet - Oral
5 MG
4/24/1997

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.